Current Standard of Care in Patients with Myelodysplastic Syndromes and Future Perspectives
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal disorders caused by somatic driver mutations affecting the hematopoietic stem and progenitor cells (HSPCs). MDS are characterized by ineffective hematopoiesis with inflammation, dysplasia, cytopenia, and a variable risk of...
Main Authors: | Ioannis Chanias, Nicolas Bonadies |
---|---|
Format: | Article |
Language: | English |
Published: |
THE HEALTHBOOK COMPANY LTD.
2020-12-01
|
Series: | healthbook TIMES. Oncology Hematology |
Online Access: | https://doi.org/10.36000/hbT.OH.2020.06.026 |
Similar Items
-
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
by: Ioannis Chanias, et al.
Published: (2021-06-01) -
Diagnostic Approach, Clinical Implications and Management of Clonal Cytopenia of Undetermined Significance
by: Ioannis Chanias, et al.
Published: (2022-12-01) -
Management of patients with lower-risk myelodysplastic syndromes
by: Andrew M. Brunner, et al.
Published: (2022-12-01) -
The future of myelodysplastic syndrome—patient priorities and outcomes that matter
by: Matthew Poynton, et al.
Published: (2023-12-01) -
P1728: THE FUTURE OF MYELODYSPLASTIC SYNDROME – PATIENT PRIORITIES AND OUTCOMES THAT MATTER
by: M. Poynton, et al.
Published: (2022-06-01)